Glucagon-like Peptide 1, total (GLP-1 total)

Glucagon-like Peptide 1 (GLP-1) consists of two biologically active forms, GLP-1 (7-37) and GLP-1 (7-36). GLP-1 has several physiological properties that may make it useful as a potential treatment for diabetes mellitus. GLP-1 increases insulin secretion and decreases glucagon secretion from the pancreas. Other functions include the inhibition of acid secretion and gastric emptying in the stomach, an increase in beta cell mass and insulin gene expression and a decrease in food intake due to increased satiety. Once GLP-1 enters the blood stream it has a half life of less than two minutes due to rapid degradation by the enzyme DPP-1V.

Swiss-Prot Accession Number: P01275


 
Therapy Indications
 
Publications
Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment (2018) van den Ham HJ, Cooper J, Tomasik J, Bahn S, Aerts J, Oseterhaus A, Gruters R, Andeweg A PLoS One
Blood profiling of proteins and steroids during weight maintenance with manipulation of dietary protein level and glycaemic index (2012) Wang P, Holst C, Astrup A, Bouwman FG, van Otterdijk S, Wodzig WK, Andersen MR, van Baak MA, Rasmussen LG, Martinez JA, Jebb SA, Pfeiffer AF, Kafatos A, Handjieva-Darlenska T, Hlavaty P, Saris WH, Mariman EC Br J Nutr. 2012 Jan;107(1):106-19
Identification of targeted analyte clusters for studies of schizophrenia. (2010) Cheng TM, Lu YE, Guest PC, Rahmoune H, Harris LW, Wang L, Ma D, Stelzhammer V, Umrania Y, Wayland MT, Lió P, Bahn S Mol Cell Proteomics 9: 510-522.